Neovasc Inc. (NVCN) |
| 30.03 0 (0%) 04-10 16:00 |
| Open: | 29.59 |
| High: | 30.07 |
| Low: | 29.43 |
| Volume: | 1 |
| Market Cap: | 83(M) |
| PE Ratio: | -1.99 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 35.12 |
| Resistance 1: | 30.07 |
| Pivot price: | 29.82 |
| Support 1: | 29.43 |
| Support 2: | 29.04 |
| 52w High: | 30.07 |
| 52w Low: | 4.585 |
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Financials
| EPS | -15.070 |
| Book Value | 10.220 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 25 Feb 2026
TRT Presents World Citizen Awards At Istanbul Ceremony - Universe News Network
Tue, 24 Feb 2026
Karaca Targets UK Ramadan Market With Practical Homeware Range - Universe News Network
Wed, 07 Jan 2026
Pharmaceutical Trade Agreements Promise Greater Stability For Patients - Universe News Network
Wed, 18 Jan 2023
Shockwave to pay $100M for Neovasc, adding refractory angina treatment to device pipeline - MedTech Dive
Wed, 18 Jan 2023
The Funded: Shell plans to buy struggling Bay Area EV charging business Volta - The Business Journals
Tue, 17 Jan 2023
Shockwave Medical to acquire Neovasc for up to $147M - MassDevice
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
